Isracann Biosciences Inc. announced earnings results for the third quarter ended February 28, 2021. For the third quarter, the company announced net loss was CAD 1.670 million compared to CAD 4.925 million a year ago. Basic loss per share was CAD 0.01 compared to CAD 0.04 a year ago. For the nine months, net loss was CAD 3.924 million compared to CAD 8.488 million a year ago. Basic loss per share was CAD 0.03 compared to CAD 0.11 a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.1 a year ago.